Viral Hemorrhagic Fever Clinical Trials

Find Viral Hemorrhagic Fever Clinical Trials Near You

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial

Who is this study for? Patients with dengue fever
What treatments are being studied? Zanamivir
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 7
Healthy Volunteers: f
View:

• Provision of signed and dated informed consent form.

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• Male or female, aged \>7 years

• Willingness to receive intravenous medication and be willing to adhere to the medication regimen

• Have a diagnosis of dengue by dengue NS1 rapid test

• Have had a self-informed fever \>38 degrees C in the last 3 days.

• Have dengue with warning signs as per the 2009 WHO criteria including one of the following: abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, restlessness, liver enlargement over 2 cm, augmented hematocrit, thrombocytopenia or severe dengue defined as dengue with severe plasma leakage leading to dengue shock and/or fluid accumulation with respiratory distress; severe hemorrhage; severe organ impairment (hepatic damage, renal impairment, cardiomyopathy, encephalopathy or encephalitis).

• Enrollment in EPS (Entidadas Promotoras de Salud) or Sistema General de Seguridad Social en Salud (SGSSS)- Colombian Public Health Insurance.

Locations
Other Locations
Colombia
Cien Salud IPS SAS
ACTIVE_NOT_RECRUITING
Barranquilla
Clinica de la Costa SAS
RECRUITING
Barranquilla
Contact Information
Primary
Aileen Y Chang, MD
chang@email.gwu.edu
202-741-6562
Backup
Alfonso Sucerquia, MD
alfonso.sucerquiahernandez@email.gwu.edu
202-741-6562
Time Frame
Start Date: 2024-03-15
Estimated Completion Date: 2027-08-31
Participants
Target number of participants: 74
Treatments
Experimental: Zanamivir
In the treatment group, participants weighing less than 50 kg will receive 12 mg/kg and those weighing 50 kg and above will receive 600 mg as the initial dose intravenously every twelve hours for 5 days adjusted for renal function.
Placebo_comparator: Placebo
In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
Related Therapeutic Areas
Sponsors
Collaborators: Clinica de la Costa, Global Disease Research, Universidad Libre de Barranquilla, Naval Medical Research Center
Leads: George Washington University

This content was sourced from clinicaltrials.gov